What happened with AGIO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Agios Pharmaceuticals’ commercial business centers on mitapivat, sold under two brands. PYRUKYND treats hemolytic anemia in adults with pyruvate kinase (PK) deficiency; AQVESME treats anemia in adults with alpha- or beta-thalassemia and launched in the United States in early 2026. U.S. PYRUKYND sales have supplied most product revenue. Specialty distributors and specialty pharmacies buy PYRUKYND from Agios, then resell it to pharmacies or dispense it to patients.
One customer accounts for the vast majority of revenue. Outside the United States, Agios relies on NewBridge Pharmaceuticals in the Gulf Cooperation Council region and Avanzanite Bioscience in the European Economic Area, Switzerland and the United Kingdom. These partners handle distribution and local commercialization, including pricing and reimbursement arrangements. Agios also provides patient access through a managed access program, with some medicines supplied free and others for payment.
Sales depend on physicians prescribing the medicines, patients continuing treatment and payors covering the cost. Agios relies entirely on outside manufacturers for drug supply. AQVESME is available only through an FDA-approved safety program, called REMS, to address liver-injury risk; this restricts how it can be supplied. Agios also continues clinical development and relies on cash reserves to help fund the business while building product revenue.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Agios’s results hinge on adoption of mitapivat for rare anemias, with Bristol-Myers Squibb’s Reblozyl—a beta-thalassemia rival absent from this list—a company and product to watch.
CRISPR Therapeutics competes with Agios’s AQVESME for patients with transfusion-dependent beta-thalassemia through its gene-editing treatment CASGEVY, and also challenges Agios’s sickle cell development program. CASGEVY’s uptake in eligible beta-thalassemia patients is the overlap to watch.
Fulcrum Therapeutics is developing oral pociredir for sickle cell disease and exploring its use in some types of beta-thalassemia, putting it alongside Agios’s blood-disease treatments and development programs. Pociredir’s clinical progress, rather than current medicine sales, is what matters for this rivalry.
Vertex sells CASGEVY for transfusion-dependent beta-thalassemia and sickle cell disease, competing with Agios’s marketed thalassemia treatment and its sickle cell development program.
Beam Therapeutics is developing genetic medicines for the same sickle cell patients Agios aims to treat through a different approach; Beam currently earns revenue mainly from licensing and collaborations, not medicine sales. Watch its sickle cell candidates’ efficacy, safety and convenience, which Beam identifies as factors in competition.
Disc Medicine’s DISC-3405 directly competes with Agios’s AG-236 in development for polycythemia vera: both target TMPRSS6 within their blood-disease programs.
PTC Therapeutics already sells Sephience for phenylketonuria, the disease Agios is targeting with investigational AG-181. Sephience sales are the relevant part of PTC’s rare-disease medicine revenue to watch for this future competition.
Maze Therapeutics’ MZE-782 and Agios’s AG-181 are competing candidates for phenylketonuria, so this tie concerns future treatments rather than current sales. Watch MZE-782’s progress in phenylketonuria specifically: Maze also develops it for chronic kidney disease and has no product-sales revenue.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of interest rates that can affect the interest income Agios earns on its cash.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, interest income on Agios’s cash may rise; higher borrowing costs could also matter if the company borrows.
If it comes in below expectations
If the Fed sets rates lower than expected, interest income on Agios’s cash may fall; borrowing costs could ease if the company borrows.
Fulcrum Therapeutics, Inc. earningsFULC
Fulcrum Therapeutics's report will show how its oral candidate pociredir is progressing in sickle cell disease, where it could eventually compete with Agios for patients.
Look for pociredir's clinical progress in sickle cell disease and any reported evidence on efficacy and safety. Progress supported by encouraging results would make Fulcrum a stronger potential rival for the same patients Agios aims to treat; stalled development or unconvincing evidence would weaken that threat, but would not prove Agios's candidates work or that demand is stronger.
PTC Therapeutics, Inc. earningsPTCT
PTC Therapeutics's report will show how its marketed phenylketonuria medicine Sephience is selling, offering a market reference for Agios's investigational AG-181.
Watch Sephience sales or any reported uptake; PTC's total revenue is not a stand-in for this one medicine. Growing use and sales would show that a marketed treatment is gaining ground among people with phenylketonuria and that AG-181 would face an established option; weak results would show limited traction for Sephience, not that patient demand is absent or AG-181 has no opportunity.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex's report will show whether its gene-editing treatment CASGEVY is reaching people with transfusion-dependent beta-thalassemia, the same patient group Agios targets with AQVESME.
Look for Vertex's reported CASGEVY treatment numbers or uptake specifically in transfusion-dependent beta-thalassemia; total CASGEVY sales alone do not show which disease is driving growth. Rising use in this group would mean eligible patients for AQVESME have another treatment option and competition is more tangible; limited use, or overall sales growth without evidence from this group, would not establish significant pressure on AQVESME.
Agios Pharmaceuticals, Inc. earningsThis company
Agios's report will show whether PYRUKYND sales are holding up and whether its newly launched AQVESME is beginning to add a second source of product revenue.
Read net product revenue by product and region, alongside any disclosed AQVESME sales. If PYRUKYND revenue keeps growing and AQVESME begins to contribute, Agios is building sales beyond its established product; if PYRUKYND weakens while AQVESME adds little, the business has not yet broadened its product base.
Disc Medicine, Inc. earningsIRON
Disc Medicine's report will show how its polycythemia vera candidate DISC-3405 is progressing; it targets the same mechanism as Agios's AG-236.
Read DISC-3405's clinical progress in polycythemia vera alongside any safety and efficacy evidence. If the program advances with supportive data, Agios's AG-236 faces a closer rival aimed at the same target; if development stalls or the evidence is weak, the visible direct threat is lower, but that does not establish that AG-236 will succeed.
